MedTrace Logo

Comparison of Hyaluronic Acid, Injectable Platelet-Rich Fibrin, and Prolotherapy in TMJ Arthrocentesis

NCT07479693 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-03-18

No results posted yet for this study

Summary

This study aimed to compare the clinical effectiveness of different intra-articular adjunctive therapies used with temporomandibular joint (TMJ) arthrocentesis in patients with temporomandibular joint disorders. TMJ arthrocentesis is a minimally invasive procedure commonly used to reduce pain and improve mandibular function in patients with internal derangements of the temporomandibular joint. In this study, patients diagnosed with TMJ disorders were treated with arthrocentesis alone or arthrocentesis combined with intra-articular injection of hyaluronic acid, injectable platelet-rich fibrin (i-PRF), or dextrose prolotherapy. Clinical outcomes including pain intensity, mandibular range of motion, and functional improvement were evaluated at different follow-up periods. The aim of this study was to compare the effectiveness of these adjunctive treatments and to determine whether any of these intra-articular approaches provides superior clinical outcomes when used with TMJ arthrocentesis.

Conditions

  • Temporomandibular Joint Pain
  • Arthrocentesis

Interventions

PROCEDURE

Temporomandibular Joint Arthrocentesis

Temporomandibular joint arthrocentesis was performed using a standard two-needle technique to lavage the superior joint space and remove inflammatory mediators.

DRUG

Hyaluronic Acid (Orthovisc)

Intra-articular injection of hyaluronic acid (Orthovisc) into the temporomandibular joint following arthrocentesis.

BIOLOGICAL

Injectable Platelet-Rich Fibrin (i-PRF)

Autologous injectable platelet-rich fibrin prepared from the patient's venous blood and injected intra-articularly into the temporomandibular joint following arthrocentesis.

DRUG

Dextrose prolotherapy (DPT)

Intra-articular injection of dextrose solution administered as prolotherapy into the temporomandibular joint following arthrocentesis.

Sponsors & Collaborators

  • Ondokuz Mayıs University

    lead OTHER

Principal Investigators

  • Emel Bulut, DDS, PhD · Ondokuz Mayıs University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2025-08-01
Completion
2025-08-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07479693 on ClinicalTrials.gov